Bertilimumab
Bertilimumab Basic information
- Product Name:
- Bertilimumab
- Synonyms:
-
- Bertilimumab [inn]
- Cat-213
- Human anti-eotaxin 1 monoclonal antibody
- Immunoglobulin G4, anti-(human eotaxin 1) (human monoclonal cat-213 gamma 4-chain), disulfide with human monoclonal cat-213 kappachain, dimer
- Bertilimumab
- Research Grade Bertilimumab
- CAS:
- 375348-49-5
- MW:
- 0
- Mol File:
- Mol File
Bertilimumab Usage And Synthesis
Uses
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research[1].
in vivo
Bertilimumab (CAT 213) (0.01-10 mg/kg) administered i.v. 30 min before i.po. injection of human eotaxin1 (1 μg) causes a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. Bertilimumab also significantly inhibits neutrophil and mononuclear cell influx into the air pouch, which resulted in a dose-related inhibition of total cell influx[1].
| Animal Model: | Female BALB/c mice (17-21 g) injected human eotaxin1[1]. |
| Dosage: | 0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, 10 mg/kg |
| Administration: | i.v; once |
| Result: | Caused a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. |
References
[1] Sarah Main, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404. DOI:10.1124/jpet.106.110734
BertilimumabSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com